Pharmacovigilance In-Depth Industrial and Market studies (Phases of Drug Development: Preclinical Studies, Clinical Trial Phase I, II, III & IV or Post Marketing Surveillance; Type of Methods: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, & EHR Mining; Type of Service: In-House & Contract Outsourcing) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 - 2020
Albany, New York, Mar 01, 2017
"Pharmacovigilance
Market (Phases of Drug Development: Preclinical Studies, Clinical
Trial Phase I, II, III & IV or Post Marketing Surveillance; Type
of Methods: Spontaneous Reporting, Intensified ADR Reporting,
Targeted Spontaneous Reporting, Cohort Event Monitoring, & EHR
Mining; Type of Service: In-House & Contract Outsourcing) -
Global Industry Analysis, Size, Share, Growth, Trends and Forecast,
2017 - 2020"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Intensifying
regulatory expectations, tougher inspection system, and instant need
for patient reporting boost the adoption rate of pharmacovigilance
among pharmaceutical companies. Rise in the prevalence of acute and
chronic diseases has consequently led to an increase in the
incidences of drug consumption, thus leading to growth in the number
of adverse drug events and drug toxicity cases. Furthermore, safety
regulations, risk of high-profile safety issues, large volume of
post-market events to be reviewed along with negative media coverage
have bound the pharmaceutical players to take support of various
outsourcing services for drug monitoring.
Two
major outsourcing providers preferred by pharmaceutical manufacturers
for pharmacovigilance services are namely, traditional CROs (e.g.
Covance, Inc., Quintiles Transnational, INC Research, etc.) and BPOs
(e.g. Capgemini, Cognizant, Infosys Ltd., Tata Consultancy Services
Limited, etc.). Outsourcing services do not only help in cost saving,
but also support process efficiency. Pharmaceutical companies are now
entering into long-term partnerships/service agreements with CROs and
BPOs to reduce the pharmacovigilance process related expenditure,
incurred right from drug discovery to post-marketing approvals. In
addition, pharmacovigilance requires skilled resources with excellent
language skills and strong knowledge pertaining to case reporting due
to which pharmaceutical companies are opting for outsourced
pharmacovigilance services in order to reduce the burden of clerical
functions as well as capital expenditures.
This report provides a detailed analysis of the global
pharmacovigilance market and assists in understanding various market
regulating factors. The market overview section in this report
provides analysis of the overall market trends and market dynamics
such as market driving factors, restraining factors, and
opportunities, which currently administrate the dynamics of the
overall pharmacovigilance market. Additionally, the segment also
provides and predicts the future circumstances of the market. Market
monitoring tools such as Porter’s five forces analysis is also
included in this study to provide analysis about the competition in
the pharmacovigilance market and market attractiveness in various
regions across the world. Competitive analysis tools such as market
share analysis and market attractive analysis have also been included
in the market overview section of the report to deliver a
comprehensive status of the players in the global pharmacovigilance
market. The executive summary provided in this report reflects the
highlights of the study scope and the overall market in a summarized
form. Furthermore, it includes a market snapshot, which provides a
glance at the current scenario of the global pharmacovigilance market
in terms of current and future market size and growth.
–
Table of Contents
Chapter
1 Introduction
1.1
Report Description
1.2
Research Methodology
1.3
Market Segmentation
Chapter
2 Executive Summary
Chapter
3 Global Pharmacovigilance Market Dynamics
3.1
Introduction
3.2
Market Drivers
3.2.1
Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug
Event Monitoring
3.2.2
Rise in the Cases of Adverse Drug Reactions and Drug Toxicity Would
Boost Demand for Pharmacovigilance Activities
3.2.3
Rise in Adoption of Outsourcing Services Expected to Accentuate the
Market Growth
3.3
Market Restraints
3.3.1
High Risk Associated with Data Security in Pharmacovigilance
Outsourcing
3.3.2
Lack of Availability of Skilled Labor might Hinder the Market Growth
3.3.3
Inadequate Pharmacovigilance System for Herbal Products in Asia
Pacific Might Hamper the Market Growth
3.4
Market Opportunities
3.4.1
Huge Scope for Rapid Growth of Pharmacovigilance Market in Emerging
Economies
3.4.2
Shift in Preference for Outsourcing among Various Pharmaceutical and
Life Sciences Companies
3.5
Porter’s Five Forces Analysis: Global Pharmacovigilance Market
3.5.1
Bargaining Power of Suppliers
3.5.2
Bargaining Power of Buyers
3.5.3
Threat of Substitutes
3.5.4
Threat of New Entrants
3.5.5
Competitive Rivalry
3.6
Market Attractiveness Analysis: Global Pharmacovigilance Market, by
Geography
3.7
Competitive Landscape
3.7.1
Market Share Analysis: Global Pharmacovigilance Market, 2013 (Value
%)
Chapter
4 Global Pharmacovigilance Market, by Phases of Drug Development
4.1
Overview
4.1.1
Global Pharmacovigilance Market Revenue, by Phases of Drug
Development, 2012 – 2020 (USD Million)
4.1.2
Comparative Analysis: Global Pharmacovigilance Market Revenue, by
Type of Clinical Trial Phases, 2013 & 2020 (Value %)
4.2
Preclinical Studies
4.2.1
Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 –
2020 (USD Million)
4.3
Phase I
4.3.1
Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012
– 2020 (USD Million)
4.4
Phase II
4.4.1
Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012
– 2020 (USD Million)
4.5
Phase III
4.5.1
Global Phase III Clinical Trial Pharmacovigilance Market Revenue,
2012 – 2020 (USD Million)
4.6
Phase IV or Post Marketing Surveillance
4.6.1
Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012
– 2020 (USD Million)
Chapter
5 Global Pharmacovigilance Market, By Type of Methods
5.1
Overview
5.1.1
Global Pharmacovigilance Market Revenue, by Type of Methods , 2012 –
2020 (USD Million)
5.1.2
Comparative Analysis: Global Pharmacovigilance Market Revenue, by
Type of Methods, 2013 & 2020 (Value %)
5.3
Spontaneous Reporting
5.3.1
Global Spontaneous Reporting Market Revenue, 2012 – 2020 (USD
Million)
5.4
Intensified ADR Reporting
5.4.1
Global Intensified ADR Reporting Market Revenue, 2012 – 2020 (USD
Million)
5.5
Targeted Spontaneous Reporting
5.5.1
Global Targeted Spontaneous Reporting Market Revenue, 2012 – 2020
(USD Million)
5.6
Cohort Event Monitoring
Comments
Post a Comment